The discovery of novel calcium sensing receptor negative allosteric modulators
Graphical abstract
The discovery of a structurally novel, orally bioavailable series of calcium sensing receptor negative allosteric modulators is described.
References and notes (13)
- et al.
Bone
(2003) - et al.
J. Med. Chem.
(2002)et al.J. Med. Chem.
(1997)et al.J. Chem. Soc., Perkin Trans. 2
(1989) - et al.
Xenobiotica
(2006) - et al.
N. Eng. J. Med.
(2007) - et al.
Treat. Endocrinol.
(2006) - et al.
Endocrinology
(1993)
Cited by (37)
Allosteric modulators targeting GPCRs
2019, GPCRs: Structure, Function, and Drug DiscoveryDiscovery and Development of Calcimimetic and Calcilytic Compounds
2018, Progress in Medicinal ChemistryCitation Excerpt :This diastereoisomer showed no significant activity (> 10 μM) in a panel of screens to assess off-target pharmacology, with no activity at the hERG channel or P450 enzymes. No significant adverse effects were observed dosing at 500 mg/kg for 4 days in a rat study [137]. There is no available evidence showing that this compound advanced into clinical trials.Unlabelled Image
Molecular insights into allosteric modulation of Class C G protein-coupled receptors
2017, Pharmacological ResearchCitation Excerpt :Thus, efforts were focused on developing a short-lived NAM in an attempt to achieve bursts of PTH release that would stimulate bone formation. Indeed, the second-generation CaSR NAM, ronacaleret, was rapidly metabolised in comparison to NPS-2143 [163]. However, even with the desired pharmacokinetic profile, preclinical and clinical studies indicated plasma PTH levels remained above baseline for at least 8 hours post ronacaleret administration, in contrast to no more than 4 hours following injection of PTH1-34 [164].
Novel therapies in benign and malignant bone diseases
2012, Pharmacology and TherapeuticsCitation Excerpt :Several first generation calcilytic programmes were discontinued due to their narrow therapeutic index. At present, several calcilytics with more favourable pharmacologic properties are assessed in clinical trials (Balan et al., 2009; Kumar et al., 2010). The most advanced, MK-5442 is an oral calcilytic which has been evaluated in two phase 2 trials in (NCT00996801 and NCT00960934) approximately 900 postmenopausal women.
Dimers and beyond: The functional puzzles of class C GPCRs
2011, Pharmacology and TherapeuticsCitation Excerpt :Furthermore, recently, a phase II trial on osteoporosis of the calcilytic drug, Ronacaleret (SB-751689) conducted by the partnership of NPS Pharmaceuticals Inc. and GlaxoSmithKline had been prematurely discontinued due to a lack of clinical efficacy. However, calcilytic compounds, which are more potent than Ronacaleret in rat model, have recently been discovered (Balan et al., 2009). As described here, the unique structural features of class C GPCRs are reflected in their particular molecular mechanisms of action.
Osteoporosis: Now and the future
2011, The LancetCitation Excerpt :These compounds led to sustained PTH secretion and findings that were reminiscent of primary hyperparathyroidism, a catabolic bone disease. Currently, newer calcilytic drugs with an improved pharmacological profile are being assessed.77,78 The most advanced compound of this class is MK-5442, which is currently in phase-2 trials for postmenopausal osteoporosis.